Table 3.
Analysis of the association between EGF A61G and progression-free survival (PFS) in main models
| M3: GG+AG vs. AA | M4: GG vs. AA | M5: AG vs. AA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| Study groups | Studies Numbers | HR (95% CI) | P | I2 | HR (95% CI) | P | I2 | HR (95% CI) | P | I2 |
| Overall | 4 | 0.80 (0.54-1.18) | 0.26 | 72% | 0.65 (0.36-1.31) | 0.25 | 63% | 0.72 (0.54-0.96) | 0.02 | 35% |
| Therapy regimens | ||||||||||
| C alone | 2 | 0.86 (0.32-2.34) | 0.76 | 87% | 1.01 (0.27-3.78) | 0.99 | 76% | 0.83 (0.57-1.20) | 0.02 | 41% |
| C combine | 1 | 0.80 (0.58-1.20) | 0.28 | 61% | 0.47 (0.27-0.81) | 0.01 | -- | 0.58 (0.37-0.92) | 0.32 | -- |
C alone: cetuximab used as single agent; C combine: cetuximab used in combination with irinotecan or oxaliplatin based chemotherapy.